Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)

a study on Prostate Cancer

Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
estimated completion

Description

Summary

A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.

Official Title

A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer

Keywords

Prostate Cancer Primary Prostate Cancer Diagnostic Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Scan Prostatic Neoplasms rhPSMA-7.3 (18F) Injection

Eligibility

You can join if…

Open to males ages 18 years and up

  1. Patient is male and aged >18 years old.
  2. Histologically confirmed adenocarcinoma of the prostate.
  3. Patients electing to undergo Radical Prostatectomy (RP) with Pelvic lymph node dissection (PLND).

You CAN'T join if...

  1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer <24 hours prior to the PET scan.
  2. Patients currently receiving, or with a prior history of, Androgen Deprivation Therapy (ADT).

Locations

  • University of California Irvine Medical Center (UCIMC) accepting new patients
    Orange California 92868 United States
  • John Wayne Cancer Institute accepting new patients
    Santa Monica California 90403 United States
  • Tower Urology accepting new patients
    Los Angeles California 90048 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Blue Earth Diagnostics
ID
NCT04186819
Phase
Phase 3
Study Type
Interventional
Last Updated